A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E

被引：0
|
作者：
Kottschade, L. A.
Suman, V. J.
Amatruda, T., III
McWilliams, R. R.
Dakhil, S. R.
Nikcevich, D. A.
Morton, R. F.
Fitch, T. R.
Jaslowski, A. J.
Markovic, S. N.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Metro Minnesota CCOP, St Louis Pk, MN USA
[3] Wichita Community Clin Oncol, Wichita, KS USA
[4] Duluth CCOP, Duluth, MN USA
[5] Iowa Oncol Res Assoc CCOP, Des Moines, IA USA
[6] Mayo Clin Scottsdale, Scottsdale, AZ USA
[7] St Vincent Reg Canc Ctr CCOP, Green Bay, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.9044
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9044
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ABI-007 in the treatment of unresectable or recurrent gastric cancer refractory to fluoropyrimidine-containing regimen: Updated data from the multicenter phase II study.
    Takiuchi, Hiroya
    Sasaki, Yasutsuna
    Nishina, Tomohiro
    Yasui, Hirofumi
    Muro, Kei
    Tsuji, Akihito
    Koizumi, Wasaburo
    Toh, Yasushi
    Hara, Takuo
    Miyata, Yoshinori
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [22] Phase I trial of escalating doses of ABI-007 (nanoparticle albumin-bound paclitaxel) and gemcitabine in patients (pts) with thoracic malignancies
    Lee, C. B.
    Stinchcombe, T. E.
    Socinski, M. A.
    Hayes, D. N.
    Goldberg, R. M.
    Hawkins, M. J.
    Obasaju, C. K.
    Dees, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Phase II study of E7070 in patients with metastatic melanoma (stage IV)
    Aamdal, S
    Smyth, J
    Awada, A
    Dittrich, C
    Caponigro, F
    Djurasinovic, N
    Marchal, B
    Yule, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S50 - S50
  • [24] Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma
    Geoerger, Birgit
    Bergeron, Christophe
    Gore, Lia
    Sender, Leonard
    Dunkel, Ira J.
    Herzog, Cynthia
    Brochez, Lieve
    Cruz, Ofelia
    Nysom, Karsten
    Berghorn, Elmer
    Simsek, Burcin
    Shen, Jun
    Pappo, Alberto
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 358 - 363
  • [25] RANDOMIZED PHASE II STUDY OF DACARBAZINE (DTIC) WITH OR WITHOUT CARBOPLATIN (CBDCA) IN PATIENTS WITH STAGE IV CUTANEOUS MELANOMA
    Babovic, N.
    Matkovic, S.
    Ursulovic, T.
    Kreacic, M.
    Milosavljevic, M.
    Jelic, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 241 - 241
  • [26] Phase II trial on nivolumab in patients with unresectable or metastatic mucosal melanoma
    Nomura, M.
    Andoh, M.
    Yokota, T.
    Miyazaki, T.
    Satake, H.
    Iwasawa, S.
    Sonoda, A.
    Kato, K.
    Muto, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Preliminary results from a multicenter phase II trial of biweekly neoadjuvant gemcitabine, epirubicin, ABI-007 (GEA) with correlative SPARC tumor analysis.
    Yardley, D. A.
    Meluch, A.
    Murphy, P.
    Doss, H.
    Simons, L.
    Hart, L.
    Daniel, B.
    Burris III, H. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S147 - S147
  • [28] Final results of a phase II immunotherapy trial for stage III and IV melanoma patients.
    Riker, Adam Irwin
    Rossi, Gabriela R.
    Alsfeld, Leonard C.
    Denham, Fiona
    Tennant, Lucinda
    Ramsey, William Jay
    Link, Charles J.
    Harrison, Marilynn
    Vahanian, Nicholas N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Phase II Study of ABI-007 Given as an Every Three Weeks Schedule for Japanese Patients With Unresectable or Recurrent Gastric Cancer Refractory to 5-fluorouracil (5-FU) Containing Regimen
    Nishina, T.
    Sasaki, Y.
    Yasui, H.
    Takiuchi, H.
    Tsuji, A.
    Muro, K.
    Koizumi, W.
    Toh, Y.
    Hara, T.
    Miyata, Y.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S465 - S465
  • [30] CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
    Lau, Peter Kar Han
    Harris, Samuel John
    Eastgate, Melissa A.
    Kee, Damien
    Mant, Andrew
    Nott, Louise M.
    Gedye, Craig
    Inderjeeth, Andrisha Jade
    Underhill, Craig
    Weppler, Alison Margaret
    Wallace, Roslyn
    Lee, Belinda
    Au-Yeung, George
    Williams, Narelle
    Ospino, Daniel Ariza
    Gonzales, Louise
    Shackleton, Mark J.
    Lo, Serigne N.
    McArthur, Grant A.
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345